Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.

Employees

339

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-26	₹285.90	+4.99%	16,950
26-08-25	₹272.30	+4.99%	5,980
26-08-24	₹259.35	+5.00%	9,744
26-08-21	₹247.00	+1.98%	3,565
26-08-20	₹242.20	-1.98%	84

Delayed Quote Bombay S.E.

More quotes

Delayed Bombay S.E. 02:27:03 2026-08-26 EDT			5-day change	1st Jan Change
285.90 ^INR	+4.99%		+15.70%	+84.21%

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI

Market Cap	6.32B 66.32M 56.83M 53.25M 48.64M 91.79M 92.7M 628M 245M 3.19B 249M 244M 10.56B	P/E 2025	42.6x	P/E 2026	23.3x
Enterprise Value	6.68B 70.03M 60.01M 56.23M 51.36M 96.93M 97.89M 663M 258M 3.37B 263M 257M 11.15B	EV / Sales 2025	1.38x	EV / Sales 2026	1.95x
Free-Float	10.3%	Yield 2025 *	-	Yield 2026	-

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI
05-29	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
25-09-19	Bafna Pharmaceuticals Limited Appoints Navin Kumar as Non-Executive, Independent Director	CI
25-08-12	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-12	Bafna Pharmaceuticals Limited Approves Reconstitution of Nomination & Remuneration Committee, Effective August 12, 2025	CI
25-06-24	Bafna Pharmaceuticals Limited Announces Board and Committee Changes, Effective from June 24, 2025	CI
25-05-26	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	CI
25-04-01	Bafna Pharmaceuticals Limited Announces Resignation of Krishna Yeachuri as Independent Director and Cessation as Chairman of Nomination & Remuneration Committee, Effective March 31, 2025	CI
25-02-06	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
24-11-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
24-08-13	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

1 day	+4.99%
1 week	+15.70%
Current month	+6.76%
1 month	+14.91%
3 months	+120.69%
6 months	+168.96%
Current year	+84.21%

Bafna Pharmaceuticals Limited Stock Bombay S.E.

Stocks

BAFNAPH

INE878I01022

Pharmaceuticals

Valuation: Bafna Pharmaceuticals Limited

Chart: Bafna Pharmaceuticals Limited

Latest news : Bafna Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Bafna Pharmaceuticals Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 week	237.4	285.9
1 month	237.4	296
Current year	95	296
1 year	95	296
3 years	67.8	296
5 years	67.8	296
10 years	5.25	296

Manager	Title	Age	Since
Bansilal Mahaveer C. Bafna CEO	Chief Executive Officer	64	1980-12-31
Melagiri Sridhar DFI	Director of Finance/CFO	-	-
A. Mohanachandran CMP	Compliance Officer	-	2024-05-28

Director	Title	Age	Since
Hemalatha Shanmugam BRD	Director/Board Member	51	2020-09-09
Akilapriya C Raju BRD	Director/Board Member	-	2020-09-09
Chitra Ravichandran CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAFNA PHARMACEUTICALS LIMITED	+4.99%	+15.70%	-	-	66.32M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.43%	+0.72%	+19.58%	+71.32%	48.37B
OTSUKA HOLDINGS CO., LTD.	+1.03%	+1.33%	+54.76%	+122.50%	39.88B
CIPLA LIMITED	-1.04%	-1.13%	-11.00%	+14.41%	12.05B
ZYDUS LIFESCIENCES LIMITED	+1.69%	+3.33%	+15.53%	+79.93%	11.77B
KRKA, D. D.	+0.19%	0.00%	+30.98%	+150.00%	9.19B
GEDEON RICHTER	+0.23%	+3.33%	+26.16%	+45.77%	7.87B
ONO PHARMACEUTICAL CO., LTD.	+1.61%	+1.57%	+54.90%	-10.46%	7.25B
GLENMARK PHARMACEUTICALS LIMITED	+1.52%	+8.35%	+24.78%	+217.28%	7.1B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.95%	-8.22%	-39.88%	+16.67%	5.26B
Average	+1.04%	+0.69%	+19.53%	+78.60%	16.53B
Weighted average by Cap.	+0.37%	+1.17%	+27.13%	+85.67%

	2025	2026
Net sales	1.46B 15.3M 13.11M 12.28M 11.22M 21.18M 21.39M 145M 56.41M 736M 57.45M 56.19M 2.44B	1.51B 15.8M 13.54M 12.69M 11.59M 21.87M 22.08M 150M 58.25M 760M 59.32M 58.03M 2.52B
Net income	41.52M 436K 373K 350K 319K 603K 609K 4.13M 1.61M 20.95M 1.64M 1.6M 69.38M	111M 1.16M 998K 935K 854K 1.61M 1.63M 11.03M 4.29M 56M 4.37M 4.28M 185M
Net Debt	248M 2.6M 2.23M 2.09M 1.91M 3.6M 3.63M 24.6M 9.58M 125M 9.75M 9.54M 414M	354M 3.71M 3.18M 2.98M 2.72M 5.14M 5.19M 35.18M 13.69M 179M 13.95M 13.64M 592M